An observational study in Median Arcuate Ligament, sponsored by University of Alabama at Birmingham. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by University of Alabama at Birmingham · Observational
This is a prospective, non-randomized, single arm, single center feasibility study to investigate surgical feasibility and technical success of robotic treatment for Median Arcuate Ligament Syndrome using the Intuitive Da Vinci Single Port Robot.
This study aims to systematically collect and analyze data on patient demographics, operative details, postoperative complications, length of hospital stay, and overall recovery times following vascular surgery robotic-assisted procedures. By establishing a comprehensive database of outcomes, the study seeks to demonstrate the efficacy and safety of the DaVinci SP system, providing insights that could inform clinical practices and enhance surgical techniques in robotic-assisted laparoscopic surgery.
The purpose of this early feasibility study is to evaluate whether the Da Vinci SP system provides adequate visualization, workspace access, instrument reach, and procedural control to safely perform robotic median arcuate ligament release. The study is not powered to demonstrate superiority over existing surgical approaches.
University of Alabama at Birmingham is the lead sponsor of 1,416 studies on the registry; 278 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 128 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with median arcuate ligament syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Adult Patients (older than 22 years of age) 2. Diagnosed with Median Arcuate Ligament Compression Syndrome 3. Indicated for minimally invasive robotic approach as determined by principle investigators.
4. Elective Presentation 5. Ability to complete follow-up per protocol.
Exclusion Criteria:
Single port robotic median arcuate ligament release is being investigated as an alternative to an open surgical release.
Technical Feasibility
Successful completion of robotic median arcuate ligament release without conversion to an alternative operative approach. Technical success is defined as successful completion of all intended procedural steps including: 1. Exposure of the supraceliac aorta 2. Identification of the median arcuate ligament 3. Complete division of the median arcuate ligament 4. Division of the celiac plexus fibers 5. Absence of major vascular injury 6. Absence of unplanned conversion Technical success differs from conversion rate in that conversion rate measures only procedural completion, while technical success evaluates completion of all intended operative objectives.
Time frame: 30-days
Safety
Rate of Clavien-Dindo Grade III or greater adverse events within 30 days.
Time frame: 30-days
No study locations are listed for this record.
Plan to share: No — No Individual participant data will be shared.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →